The studies reveal that the transcriptional programs driven by key lineage specification TFs, such as CDX2, are critical determinants of tissue-site-specific susceptibility to colon cancer development by cancer driver mutations. The gene discussed is CDX2; the disease is malignant colon neoplasm.